FreeTheAI

Teleflex Completes Enrollment in Study for Longer Freesolve Scaffolds

BullishLow impact
TFX$125.12 0.75%

Teleflex Incorporated (TFX) has completed patient enrollment in its BIOMAG-LL clinical trial. The study evaluates longer 35 mm and 40 mm versions of the company's Freesolve resorbable magnesium scaffolds for treating coronary artery lesions up to 38 mm in length. Following the announcement, Teleflex shares rose 0.75% to $125.10.

The study tests whether larger scaffolds can effectively treat longer clogged vessels while reducing the need to overlap multiple devices during coronary procedures. While Freesolve is available in European and other CE-mark markets, it is not yet approved in the United States. Expanding available scaffold lengths is intended to broaden the addressable patient pool.

Investors will monitor the study's primary endpoint of target lesion failure at 12 months. Long-term tracking will extend to 60 months to build medical confidence against permanent metal stents. Teleflex is also including longer scaffold lengths in its BIOMAG-III trial to support broader international regulatory clearances.

Key points

  • Teleflex finished patient enrollment for its BIOMAG-LL study evaluating 35 mm and 40 mm Freesolve resorbable magnesium scaffolds.
  • The trial tests longer scaffolds on coronary lesions up to 38 mm to help reduce device overlap during procedures.
  • Primary results will track 12-month target lesion failure, with full safety follow-up extending to 60 months.
  • Freesolve is sold in CE-mark regions but remains unapproved in the U.S., making pivotal study data key for domestic market growth.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the main goal of Teleflex's BIOMAG-LL study?

The study evaluates 35 mm and 40 mm Freesolve resorbable magnesium scaffolds for treating coronary lesions up to 38 mm long.

Is Teleflex Freesolve approved for use in the U.S.?

No, Freesolve is currently not approved in the United States. Its current revenue potential is focused on CE-mark regions while trials proceed.

When will primary results for the BIOMAG-LL study be measured?

The study's primary endpoint measures target lesion failure at 12 months, with full patient monitoring running out to 60 months.